| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/03/2000 | WO2000005369A2 Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis |
| 02/03/2000 | WO2000005362A1 Mekk1(serine threonine kinases)-interacting fha (forkhead associated domain) protein 1 (mif1) |
| 02/03/2000 | WO2000005361A1 Human sbpsapl gene with homology to the prosaposin family of neurotrophic factors |
| 02/03/2000 | WO2000005348A1 Pneumococcal nrdg protein |
| 02/03/2000 | WO2000005270A1 Biocompatible polymers, preparation method and compositions containing same |
| 02/03/2000 | WO2000005265A2 Anti-crr2 antibodies and methods of use therefor |
| 02/03/2000 | WO2000005259A1 Secreted cysteine rich protein-6 (scrp-6) |
| 02/03/2000 | WO2000005245A2 Inhibitors of urokinase and blood vessel formation |
| 02/03/2000 | WO2000005232A1 Heterocyclic compounds as inhibitors of rotamase enzymes |
| 02/03/2000 | WO2000005225A1 Biphenyl derivatives |
| 02/03/2000 | WO2000005224A2 Heterocyclic derivatives and their use as integrin inhibitor |
| 02/03/2000 | WO2000005217A1 Imidazole compounds and their use as adenosine deaminase inhibitors |
| 02/03/2000 | WO2000005216A1 Il-8 receptor antagonists |
| 02/03/2000 | WO2000005207A1 Substituted phenylamidines with antithrombotic action |
| 02/03/2000 | WO2000005201A1 N-benzocycloalkyl-amide derivatives and their use as medicaments |
| 02/03/2000 | WO2000004954A2 Novel urokinase inhibitors |
| 02/03/2000 | WO2000004926A2 Conjugates for treating inflammatory disorders and associated tissue damage |
| 02/03/2000 | WO2000004918A2 Agents for the immunotherapy of tumoral diseases |
| 02/03/2000 | WO2000004917A2 USE OF HC gp-39 IN IMMUNE DISEASES |
| 02/03/2000 | WO2000004910A2 Low molecular weight components of shark cartilage, processes for their preparation and therapeutic uses thereof |
| 02/03/2000 | WO2000004904A1 Pharmaceutical compositions comprising hydroxylansoprazole and uses thereof |
| 02/03/2000 | WO2000004895A2 Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers |
| 02/03/2000 | WO2000004893A2 Imidazoline receptor binding compounds |
| 02/03/2000 | WO2000004892A2 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions |
| 02/03/2000 | WO2000004890A1 Use of glucose uptake enhancer for reducing apoptosis |
| 02/03/2000 | WO2000004889A1 Use of glucose uptake enhancer for reducing post-ischemic injury of the heart |
| 02/03/2000 | WO2000004868A2 Libraries of polyhydroxamates and their analogs |
| 02/03/2000 | WO2000004863A2 Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions |
| 02/03/2000 | WO2000004862A2 Bioenhanced formulations comprising eprosartan in oral solid dosage form |
| 02/03/2000 | WO1999065922A3 Prenyl transferase inhibitors |
| 02/03/2000 | WO1999064001A3 Methods and compositions for increasing penetration of hiv protease inhibitors |
| 02/03/2000 | WO1999063936A3 Novel therapeutic agents that modulate endothelin receptors |
| 02/03/2000 | WO1999063933A3 Multivalent agonists, partial agonists and antagonists of the gaba receptors |
| 02/03/2000 | WO1999063932A3 Multibinding agents that modulate the 5-ht transporter |
| 02/03/2000 | WO1999063929A3 Multibinding inhibitors of microsomal triglyceride transferase protein |
| 02/03/2000 | WO1999061444A3 Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation |
| 02/03/2000 | WO1999061097A3 Alpha emitting constructs and uses thereof |
| 02/03/2000 | WO1999059620A9 Angiostatin receptor |
| 02/03/2000 | WO1999058947A3 Modulation of molecular interaction sites on rna and other biomolecules |
| 02/03/2000 | WO1999058571A3 Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof |
| 02/03/2000 | WO1999058504A9 Novel 1,2,5-trisubstituted 1,2-dihydro-indazol-3-ones with anti-asthmatic, anti-allergic, anti-inflammatory, immuno-modulating and neuro-protective effect, method for the production and use thereof as a medicament |
| 02/03/2000 | WO1999057139A3 Pth2 receptor selective compounds |
| 02/03/2000 | WO1999050251A3 Cyclin dependent kinase inhibitors |
| 02/03/2000 | WO1999034786A3 Lipase inhibiting polymers |
| 02/03/2000 | WO1998055483A9 PYRROLO[2,1,5-cd]INDOLIZINE DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES |
| 02/03/2000 | WO1998050365A9 Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents |
| 02/03/2000 | DE19834714A1 Neue 2,3,3a,4,9,9a-Hexahydro-8-hydroxy-1H-ben[f]indole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel New 2,3,3a, 4,9,9a-hexahydro-8-hydroxy-1H-ben [f] indoles, to processes for their preparation and their use as medicaments |
| 02/03/2000 | DE19834045A1 (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin (4-amino-5-ethylpyrimidine-2-yl) -1- (2-fluorobenzyl) -1H-pyrazolo [3,4-b] pyridine |
| 02/03/2000 | DE19834044A1 Neue substituierte Pyrazolderivate New substituted pyrazole derivatives |
| 02/03/2000 | DE19831382A1 Humanes m¶3¶G-cap-spezifisches Kernimportrezeptorprotein mit einer neuen Domänenstruktur, dessen Herstellung und Verwendung Human m¶3¶G-cap-specific nuclear import receptor protein with a new domain tree, its preparation and use |
| 02/03/2000 | CA2338741A1 Il-8 receptor antagonists |
| 02/03/2000 | CA2338524A1 Inhibitors of urokinase and blood vessel formation |
| 02/03/2000 | CA2338305A1 Imidazole compounds |
| 02/03/2000 | CA2338299A1 Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions |
| 02/03/2000 | CA2338279A1 Imidazoline receptor binding compounds |
| 02/03/2000 | CA2338216A1 Use of glucose uptake enhancer for reducing post-ischemic injury of the heart |
| 02/03/2000 | CA2338211A1 Use of glucose uptake enhancer for reducing apoptosis |
| 02/03/2000 | CA2338209A1 Biphenyl derivatives |
| 02/03/2000 | CA2338198A1 N-benzocycloalkyl-amide derivatives and their use as medicaments |
| 02/03/2000 | CA2338068A1 Low molecular weight components of shark cartilage, processes for their preparation and therapeutic uses thereof |
| 02/03/2000 | CA2337756A1 Libraries of polyhydroxamates and their analogs |
| 02/03/2000 | CA2337413A1 Substituted phenylamidines,pharmaceutical compositions containing these compounds and processes for preparing them |
| 02/03/2000 | CA2337247A1 Isquinolines as urokinase inhibitors |
| 02/03/2000 | CA2336250A1 Anti-ccr2 antibodies and methods of use therefor |
| 02/03/2000 | CA2335646A1 Genes of the dead box protein family, their expression products and use |
| 02/03/2000 | CA2335326A1 Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis |
| 02/03/2000 | CA2335062A1 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions |
| 02/03/2000 | CA2334042A1 Orphan cytokine receptor |
| 02/02/2000 | EP0976744A1 Amide, carbamate, and urea derivatives having glutamate receptor function potentiating activity |
| 02/02/2000 | EP0976742A1 A synthesis of furan sulfonamide compounds useful in the synthesis of IL-1 inhibitors |
| 02/02/2000 | EP0976399A1 Propolis extract |
| 02/02/2000 | EP0975780A2 Il-2 gene expression and delivery systems and uses |
| 02/02/2000 | EP0975775A2 Regulatory system for inducible expression of genes with lambdoid promoters |
| 02/02/2000 | EP0975771A1 Type ii tgf-beta receptor/immunoglobulin constant region fusion proteins |
| 02/02/2000 | EP0975760A1 Motilin homologs |
| 02/02/2000 | EP0975758A1 POLYPEPTIDE HAVING A GTPase REGULATOR ACTIVITY, NUCLEIC ACIDS CODING THEREFOR AND THEIR USE IN DIAGNOSTICS AND THERAPY |
| 02/02/2000 | EP0975752A1 Human cerberus protein |
| 02/02/2000 | EP0975743A1 Inhibitors for urokinase receptor |
| 02/02/2000 | EP0975674A1 Immunotoxins, comprising an onc protein, directed against malignant cells |
| 02/02/2000 | EP0975661A1 The proliferation of cell-inhibiting peptide and its use |
| 02/02/2000 | EP0975650A1 Oligomers which inhibit expression of collagen genes |
| 02/02/2000 | EP0975649A1 Rnase l activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies |
| 02/02/2000 | EP0975639A1 Compounds |
| 02/02/2000 | EP0975636A1 Novel compounds |
| 02/02/2000 | EP0975633A1 5,6,7-trisubstituted-4-aminopyridol 2,3-d]pyrimidine compounds |
| 02/02/2000 | EP0975631A1 5-aryl-3-(8-azabicyclo(3.2.2)oct-3-yl)-1,3,4-oxadiazol-2(3h)-one derivatives as 5-ht4 receptor ligands |
| 02/02/2000 | EP0975629A1 Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogen receptor modulators |
| 02/02/2000 | EP0975627A1 5-(2-imidazolinylamino)benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
| 02/02/2000 | EP0975625A1 SELECTIVE FACTOR Xa INHIBITORS |
| 02/02/2000 | EP0975623A2 Indazole amide compounds as serotoninergic agents |
| 02/02/2000 | EP0975617A1 Inhibitors of cholesterol esterase |
| 02/02/2000 | EP0975614A1 A bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5ht1a, 5ht1b and 5ht1d receptor antagonistic activity |
| 02/02/2000 | EP0975612A1 Protease inhibitors |
| 02/02/2000 | EP0975609A1 Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent |
| 02/02/2000 | EP0975608A2 Halo-alkoxycarbonyl prodrugs |
| 02/02/2000 | EP0975605A1 Pyridazine and phthalazine derivatives, process of their preparation and their use as anticonvulsants |
| 02/02/2000 | EP0975596A1 Process for making 2-aryl-3-aryl-5-halo pyridines useful as cox-2 inhibitors |
| 02/02/2000 | EP0975593A1 Indole derivatives having combined 5ht1a, 5ht1b and 5ht1d receptor antagonist activity |
| 02/02/2000 | EP0975592A1 Benzyloxy prodigiosine compounds |
| 02/02/2000 | EP0975370A2 Composition and method for enhancing transport across biological membranes |